Table 1.
Demographic and baseline characteristics
| Characteristic | Controls (N = 52) | Mut-positive (N = 26) | P-value |
|---|---|---|---|
| Age at diagnosis—year | |||
| Mean | 60 | 59 | 0.83 |
| Range | 47–82 | 41–81 | – |
| Sex—no. (%) | |||
| Male | 27 (52) | 11 (42) | 0.42 |
| Female | 25 (48) | 15 (58) | |
| Race or ethnic group—no. (%)a | |||
| Asian | 3 (6) | 1 (4) | 0.76 |
| Black | 7 (13) | 0 (0) | 0.049 |
| White | 42 (81) | 25 (96) | 0.065 |
| Year at initiation of treatment | |||
| Median | 2017 | 2016 | 0.044 |
| Range | 2014–2018 | 2013–2018 | – |
| Stage—no. (%) | |||
| Locally advanced | 17 (33) | 4 (15) | 0.104 |
| Metastatic | 35 (67) | 22 (85) | |
| No. of metastatic sites involved | |||
| Median | 1 | 1 | 0.36 |
| Range | 0–3 | 0–3 | – |
| Location of metastatic sites—no. (%) | |||
| Liver | 24 (46) | 19 (70) | 0.024 |
| Lung | 7 (13) | 3 (11) | 0.81 |
| Lymph node | 11 (21) | 4 (21) | 0.54 |
| Other | 10 (19) | 4 (15) | 0.68 |
| Germline mutation—no. (%) | |||
| BRCA1 | 5 (19.2) | – | |
| BRCA2 | 17 (65.4) | – | |
| PALB2 | 4 (15.4) | – | |
A greater number of black patients were included in the control group (p = 0.0499 by the Chi-square test for comparing proportions)
aRace was reported by the investigator